In melanoma, tumors innately resistant to anti-Programmed cell death 1 (PD-1) therapy (IPRES or innate anti-PD-1 resistance) have an upregulation of the signature genes involved in EMT, cell adhesion, ECM remodeling, angiogenesis, and wound healing. The gene discussed is PDCD1; the disease is melanoma.